Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423286 · ClinicalTrials.gov registry record · Phase 1
A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07423286 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 8 participants.
The verdict
NCT07423286, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
For this study, the study medicine has been specially prepared to contain radiolabeled carbon \[14C\]. \[14C\] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study medicine does not change how the medicine works but helps to see how the medicine appears in the blood, urine, and stool after it is given. This type of study is called a radiolabeled study. The purpose of this radiolabeled study is to learn how a certain amount of \[14C\] PF-07248144 is taken up into the bloodstream and removed from the body. The study is seeking participants who are: * females who cannot have children, or males * 18 years of age or older * confirmed to be healthy based on medical and physical tests. * weigh more than 50 kilograms (kg) and have a body mass index of 18 to 32 kg per meter squared. The study consists of two parts. In part one, all participants will receive one full dose of \[14C\]PF-07248144 by mouth. Part two will begin at least 28 days after the dose in part one. In part two, participants will receive one full dose of PF-07248144 by mouth and one small dose of \[14C\] PF-07248144 by intravenous (IV) infusion. IV infusion will be directly injected into the veins. To understand how the medicine is processed in the body, samples of blood, urine, feces, and vomit (if any) will be collected after each dose is given. This will help understand: * How much PF-07248144 is taken up into the bloodstream when taken by mouth compared to the dose given by IV * How the body removes it from the blood steam. Participants will take part in the study for about 15 weeks, including evaluation at the start and follow-up period.
Interventions
- DRUG Oral [14C] PF-07248144
- DRUG Oral unlabeled PF-07248144
- DRUG IV [14C] PF-07248144
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2026-01-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07423286
The ClinicalTrials.gov registry entry for NCT07423286 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oral [14C] PF-07248144 is the first listed.
NCT07423286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07423286 about?
NCT07423286 is a clinical study titled "A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults". For this study, the study medicine has been specially prepared to contain radiolabeled carbon \[14C\]. \[14C\] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study medicine does not change how the medicine works but helps to see how the medicin...
What is the current status of trial NCT07423286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-10-13. Estimated completion is 2026-01-16.
What interventions are being tested in trial NCT07423286?
The interventions under investigation include: Oral [14C] PF-07248144 (DRUG), Oral unlabeled PF-07248144 (DRUG), IV [14C] PF-07248144 (DRUG).
Who is sponsoring clinical trial NCT07423286?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.